1. Home
  2. ABEO

as 10-07-2025 3:30pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.

Founded: 1974 Country:
United States
United States
Employees: N/A City: CLEVELAND
Market Cap: 289.2M IPO Year: 1980
Target Price: $18.17 AVG Volume (30 days): 1.1M
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 0.99 EPS Growth: N/A
52 Week Low/High: $3.93 - $7.54 Next Earning Date: 11-13-2025
Revenue: $400,000 Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 324.71%

Stock Insider Trading Activity of Abeona Therapeutics Inc. (ABEO)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Seshadri Vishwas ABEO Chief Executive Officer Sep 30 '25 Sell $5.24 25,000 $130,930.00 1,190,067
O'Malley Brendan M. ABEO SVP, Chief Legal Officer Sep 29 '25 Sell $5.39 9,366 $50,515.52 350,763
Vazzano Joseph Walter ABEO Chief Financial Officer Sep 29 '25 Sell $5.39 9,035 $48,730.27 453,631
Seshadri Vishwas ABEO Chief Executive Officer Sep 29 '25 Sell $5.39 19,274 $103,954.32 1,190,067
O'Malley Brendan M. ABEO SVP, Chief Legal Officer Sep 22 '25 Sell $5.43 688 $3,735.84 350,763
Vazzano Joseph Walter ABEO Chief Financial Officer Aug 15 '25 Sell $7.36 15,000 $110,358.00 453,631
Crombez Eric ABEO N/A Aug 14 '25 Sell $6.93 4,718 $32,683.00 42,427

Share on Social Networks: